RxDoctor Payments Data

William Pomeroy, MD

Cardiovascular Disease · Asheville, NCNPI 1548458367

Payments from drug & device makers

$179,794in general payments, 2019–2025

Across 126 payments — averaging $1426.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$100K
  • Janssen Research & Development, LLC$48K
  • Boehringer Ingelheim International GmbH$26K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$3K
  • Novartis$875
  • Novo Nordisk$267
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$3,484100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$179,794 in reported general payments places this provider in the 90th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$499,303
Medicare patients
1,601
Services billed
27,699

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban651$636,107
EntrestoSacubitril/Valsartan240$293,273
JardianceEmpagliflozin229$230,771
XareltoRivaroxaban186$218,183
Repatha SureclickEvolocumab167$142,873
FarxigaDapagliflozin Propanediol91$71,661
Praluent PenAlirocumab59$44,455
Repatha SyringeEvolocumab31$33,207
MultaqDronedarone Hcl23$26,263
NexletolBempedoic Acid37$17,925
Dofetilide60$16,474
Ranolazine ErRanolazine76$6,660
Metoprolol Succinate543$6,553
Ezetimibe219$6,535
Rosuvastatin Calcium398$5,183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$197$636,107651 claims
NovartisEntresto$875$293,273240 claims
Boehringer IngelheimJardiance$137$230,771229 claims
Johnson & JohnsonXarelto$33$218,183186 claims
AstraZenecaFarxiga$157$71,66191 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →